bevacizumab


Also found in: Thesaurus, Medical, Wikipedia.

bev·a·ciz·u·mab

 (bĕv′ə-sĭz′ə-măb′)
n.
A humanized monoclonal antibody that acts as an angiogenesis inhibitor, used intravenously to treat metastatic colorectal cancer and certain other types of cancer.

[beva-, origin unknown + -ci-, cardiovascular infix + -zu-, humanized + -m(onoclonal) a(nti)b(ody).]
References in periodicals archive ?
Bevacizumab has been applied in the treatment of cerebral radiation necrosis.
To the Editor: An outbreak of endophthalmitis associated with repackaged bevacizumab occurred during February-March 2013 in Georgia and Indiana, USA.
Hereditary hemorrhagic telangiectasia Osler Weber Rendu syndrome and management with bevacizumab
(NASDAQ: OTLK) (the 'Company'), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis) for wet AMD.
Tenders are invited for Medicinal products containing Bevacizumab
M2 PHARMA-August 16, 2019-Lynparza Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
M2 EQUITYBITES-August 15, 2019-AstraZeneca and MSD reveal phase three trial results for Lynparza in combination with bevacizumab
The trial, in the first-line maintenance setting, compared LYNPARZA added to standard-of-care bevacizumab versus bevacizumab alone in women with or without BRCA-gene mutations.
Keywords: Avastin, Bevacizumab, Branch retinal vein occlusion, Intravitreal injections, Vascular endothelial growth factor.
Global Banking News-January 29, 2019-Innovent Biologics Inc submits NDA for biosimilar product candidate of bevacizumab with the NMPA for multiple types of malignant tumors
In this study, we compared the proliferative and cytotoxic effects of asbercept (0.5 mg/mL), bevacizumab (0.3125 mg/mL), and ranibizumab (0.125 mg/mL) on RPE cell cultures by evaluating viability, apoptosis, proliferation, and senescence in control and drug-treated cells after 72 hours.